Overview

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Patients With Duchenne Muscular Dystrophy

Status:
Enrolling by invitation
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this extension study is to evaluate the ongoing safety and tolerability of additional treatment with eteplirsen administered once weekly by intravenous (IV) infusion in male DMD patients who have successfully completed the 96-week eteplirsen study: Study 4658-102 (NCT03218995)
Phase:
Phase 2
Details
Lead Sponsor:
Sarepta Therapeutics
Sarepta Therapeutics, Inc.